Effects of Daily Beef Intake, as a Component of a Heart-Healthy Diet on Cellular Zinc

Effects of Daily Beef Intake, as a Component of a Heart-Healthy Diet, on Cellular Zinc Status and Vascular Function in Older Adults

The objective of the current study is to test the overarching hypothesis that the beef nutritive matrix is uniquely suited to direct dietary zinc to cellular compartments for improved metabolic function, leading to a greater effect on health outcomes. Specifically, whether beef, as a component of a healthy meal, will promote the absorption of zinc into cells, where the zinc will have greater effects on zinc-dependent metabolic processes supporting cardiovascular health. To maximize the observability of these beef-related effects, individuals who are 55- to 70-year-old who generally have a higher risk of zinc deficiency and cardiovascular disease will be enrolled.

Study Overview

• Status: Recruiting
• Conditions: Vascular Diseases; Metabolic Diseases; Inflammation; Zinc Deficiency
• Intervention / Treatment: Other: Beef protein

Detailed Description

This study will examine whether daily beef intake will promote the absorption of dietary zinc into cells, leading to improved cellular zinc status and microvascular function. The study design will be a crossover comparison of a mixed diet including green leafy vegetables, fruits, whole grains, seeds, and nuts; with beef versus non-meat sources of additional protein and zinc, over two 4-week metabolic study periods.

Outcomes will include cellular zinc status determined by erythrocyte zinc tracer exchange (primary), and microvascular function expressed as reactive hyperemia index (RHI). Previous studies have demonstrated that zinc tracer exchange with red blood cells (RBC) is highly sensitive to changes in zinc nutriture. Thus, cellular zinc status will be determined using a novel and cost-effective adaptation of this approach, modeling zinc tracer exchange with freshly-sampled RBC. As intracellular zinc can regulate vascular tone, microvascular function will be measured, using digital peripheral tonometry, will be used as a functional index of both cellular zinc status and vascular health.

• Study Type: Interventional
• Enrollment (Estimated): 20
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Roberta R Holt, PhD; Phone Number: 15304005952; Email: rrholt@ucdavis.edu
• Study Contact Backup: Name: Andrew Hall, PhD; Email: aghall@ucdavis.edu

Study Locations

• United States
  • California
    • Davis, California, United States, 95616
      • Recruiting
      • University of California, Davis; Department of Nutrition
      • Contact: Roberta Holt, PhD; Phone Number: 530-752-4950; Email: rrholt@ucdavis.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 55 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Male or postmenopausal female 55-70 years of age
• Women: lack of menses for at least two years.
• Subject is willing and able to comply with the study protocols.
• Subject is willing to participate in all study procedures
• Self-reported stable dose of prescribed medications for a minimum of 6 months
• BMI 18.5 - 29.9 kg/m2

Exclusion Criteria:

• Self-reported use of daily anticoagulation agents including aspirin, NSAIDs
• Prescribed metaformin, statins or medications known to interfere with zinc, protein, or lipid metabolism
• Vegan, Vegetarians, food faddists or those consuming a non-traditional diet (e.g. Adkins, Keto, Paleo, etc.)
• Fruit consumption ≥ 3 cups/day
• Regular consumption of strawberries (2-3 servings/week)
• Vegetable consumption ≥ 4 cups/day
• Coffee/tea ≥ 3 cups/day
• Dark chocolate ≥ 3 oz/day
• Alcohol intake greater than 2 drinks in a day for men, or 1 drink in a day for women.
• Self-reported restriction of physical activity due to a chronic health condition
• Self-reported chronic/routine high intensity exercise
• Self-reported diabetes
• Blood pressure ≥ 140/90 mm Hg
• Self-reported renal or liver disease
• Self-reported heart disease, which includes cardiovascular events and stroke
• Peripheral artery disease Raynaud's syndrome or disease
• Inability to properly place or wear the PAT probes or abnormal measurements on pre-screening PAT
• Self-reported cancer within past 5 years
• Self-reported malabsorption
• Unwillingness to stop any supplement use six weeks prior to study initiation, including multivitamin/mineral, powders, herbal, plant or botanical, pro- and prebiotics, and oil supplements.
• Smoking, vaping, cannabis use
• Current enrollee in a clinical research study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Beef Protein; A beef stew, providing 8.8 mg zinc, 37.9 mg protein (approximately 500 kcal/d energy);	Other: Beef protein; Animal protein source
Active Comparator: Animal Protein; A control plant protein stew, providing 8.8 mg zinc, 37.9 mg protein (approximately 500 kcal/d energy);	Other: Beef protein; Animal protein source

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
microvascular function	microvascular function as measured by digital tonometry (EndoPAT2000)	4 weeks
intracellular zinc status	intracellular zinc status determined by erythrocyte zinc tracer exchange	4 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
plasma lipids	Circulating level of total cholesterol, triglycerides, HDL cholesterol, non-HDL cholesterol, with LDL cholesterol (calculated)	4 weeks
plasma fatty acids	Circulating levels of non-esterified fatty acids	4 weeks
plasma oxylipins	enzyme and non-enzyme derived non-esterified fatty acid metabolites	4 weeks

Collaborators and Investigators

• Sponsor: University of California, Davis
• Collaborators: National Cattlemen's Beef Association, a contractor to the Beef Checkoff
• Investigators: Principal Investigator: Carl L Keen, PhD, Distinguished Professor Emeritus of Nutrition

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2022
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2026

Study Registration Dates

• First Submitted: February 2, 2022
• First Submitted That Met QC Criteria: February 2, 2022
• First Posted (Actual): February 11, 2022

Study Record Updates

• Last Update Posted (Actual): February 9, 2026
• Last Update Submitted That Met QC Criteria: February 4, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Nutritional and Metabolic Diseases; Inflammation; Vascular Diseases; Metabolic Diseases
• Other Study ID Numbers: 1806393

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No